Advanced Biomed launches A+PerfusC 3D cell culture platform for precision medicine

Advanced Biomed Inc.

A+PerfusC is a compact perfusion 3D cell culture incubator with automated perfusion and environmental control, mountable on a microscope for real-time observation.
System supports up to 12 days continuous culture, 8 independent channels per plate, 600 tumor spheroids per row, and 4,800 spheroids per plate.
Global 3D cell culture market valued at $2.32B in 2025, projected to exceed $4.71B by 2030 (CAGR >15.6%) per Mordor Intelligence.
Mass-production development is ongoing; commercialization will follow finalization of mass production and quality control standards.
Potential applications include personalized oncology, drug screening, regenerative medicine, organoid studies, and stem cell research.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.